German drug industry says pricing law is restricting access to some drugsBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h6205 (Published 17 November 2015) Cite this as: BMJ 2015;351:h6205
- Ned Stafford
The German drug industry has appealed to the German government to reform its drug pricing law, saying that it is denying patients access to innovative drugs available in other European countries.
The appeal was made by the Federal Association of the German Pharmaceutical Industry (BPI) at a press conference in Berlin to mark the fifth anniversary of the approval of the law, which is widely known in Germany as AMNOG (ArzneiMittelmarkt-NeuOrdnungsGesetz; pharmaceuticals market reorganisation act).
The main goal of AMNOG was to slow the rise in drug prices, but five years ago supporters of the law also said that it would encourage innovation, because it allows drug firms to charge higher prices for new drugs with proven “added benefits” compared with drugs already on the market.
Martin Zentgraf, chairman of BPI, said at a …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial